The Inner Circle Celebrates Dr. Cha-Mei Tang's Achievements
In a remarkable acknowledgment of excellence, Dr. Cha-Mei Tang has been recognized by The Inner Circle as a Pinnacle Professional Member Inner Circle of Excellence. This esteemed recognition highlights her invaluable contributions to the field of cancer diagnostics, particularly through her pioneering work on the innovative blood test that detects cancer using tumor-associated cells. This important work is primarily conducted by the Creatv Bio Division of Creatv MicroTech.
Groundbreaking Contributions to Cancer Diagnostics
Dr. Cha-Mei Tang, a prominent figure in cancer research, has dedicated over 15 years to enhancing technologies that significantly impact cancer care. Her relentless pursuit of innovation led to the development of the LifeTracDx® blood test, which represents a major advancement in cancer diagnostics. Since the foundation of her microfabrication company in 2010, Dr. Tang has focused on optimizing methods to isolate circulating tumor cells (CTCs) from the blood of patients diagnosed with cancer.
From the initial patient sample analyzed, her research team discovered an extraordinary set of large cells that had previously evaded notice by many cancer researchers. Under her guidance, her colleague Daniel L. Adams, who now serves as the Chief Scientific Officer, conducted a systematic analysis of these cells. They identified these cells as macrophages that had taken in tumor cells, classifying them as cancer-associated macrophage-like cells (CAMLs).
The Impact of CAMLs in Cancer Screening
The work conducted by Creatv has established that CAMLs are among the most promising biomarkers used in cancer diagnostics and screening. They are present in various types of cancer and across all stages but remain absent in healthy individuals, which makes them an excellent indicator for early cancer detection. The quantity and characteristics of CAMLs can provide critical insights into a patient's cancer condition, including their prognosis and the likely effectiveness of treatments.
Dr. Tang's dedication to advancing cancer diagnostics continues to benefit many. The LifeTracDx® blood test is versatile, applicable across all cancer types, and backed by compelling clinical data. This unique test can offer real-time prognostic information, predict treatment responses within roughly 30 days of therapy initiation, and does not necessitate tissue samples for companion diagnostics.
Understanding the Significance of LifeTracDx®
One of the groundbreaking features of the LifeTracDx® blood test is its capability to monitor changes in biomarker expression, such as shifts in PD-L1 levels—an important indicator of a patient's response to immunotherapy. Additionally, it can detect cancer recurrence and minimal residual disease (MRD), thereby providing critical information that can help save lives.
Dr. Tang's Academic and Professional Background
Dr. Tang’s success is backed by her impressive academic credentials, having acquired several degrees from the Massachusetts Institute of Technology (MIT). She holds a Doctor of Science, a Master of Science, and a Bachelor of Science, all in Electrical Engineering and Computer Science. Following her education, Dr. Tang worked as Head of the Radiation and Accelerator Physics Section at the U.S. Naval Research Laboratory (NRL), where she focused on research pertaining to relativistic electron beams and free electron lasers. Her foundational research experience continues to influence her approach at Creatv MicroTech.
Throughout her illustrious career, Dr. Tang has garnered numerous awards recognizing her contributions to science and technology. She became a Fellow of the American Physical Society in 1990 and was honored as the Most Outstanding Woman Scientist in the Federal Government in 1992. Other accolades include the R&D 100 Award and her induction into Marquis Who's Who in 2024, showcasing her standing in the medical and scientific communities.
Commitment to Continued Innovation
As a leading figure in her field, Dr. Tang is actively involved in several professional organizations, including the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). The research team at Creatv consistently shares their findings at conferences and contributes to scientific literature aimed at advancing the understanding and treatment of cancer.
Recently, Creatv received CLIA approval, allowing them to conduct specific LifeTracDx® blood tests in their CLIA-certified laboratory. This initiative will initially focus on using these tests for cancer prognosis, with plans to apply for additional CLIA approvals and FDA endorsements for various cancer diagnostic applications in the near future. Dr. Tang’s vision is to create a future where cancer detection is achieved earlier, leading to more effective treatments and improved survival outcomes for patients.
Contact for additional information: Katherine Green, 516-825-5634. You can reach out to the company directly for more insights on their innovations and services.
Frequently Asked Questions
What is the LifeTracDx® blood test?
The LifeTracDx® blood test is a diagnostic tool developed to detect cancer by analyzing circulating tumor cells in the bloodstream.
How does the LifeTracDx® work?
The test captures circulating tumor cells and provides critical insights into a patient's cancer state, helping predict treatment responses and monitor disease.
What awards has Dr. Cha-Mei Tang received?
Dr. Tang has received multiple accolades, including being named a Fellow of the American Physical Society and receiving the R&D 100 Award.
What is the significance of CAMLs?
CAMLs are identified as powerful biomarkers for cancer detection, as they appear in all types of cancer but are absent in healthy individuals.
Where is Creatv MicroTech located?
Creatv MicroTech operates out of their certified laboratory and is focused on developing innovative cancer diagnostics.
